A recent post hoc analysis of the TECOS CV outcomes trial of the dipeptidyl peptidase-4 inhibitor sitagliptin found that attainment of 5 risk factor measures at baseline (aspirin use, LDL cholesterol <70 mg/dL or statin use, SBP/DBP <140/<90 mmHg, use of ACE inhibitor or angiotensin II receptor blocker, nonsmoking) was associated with reduced risk for CV death, MI, and stroke in T2D patients with established CV disease (18). The gene discussed is ACE; the disease is stroke disorder.